

October 18, 2019

## **Venturis Therapeutics Inc. Announces Granting of US Patent for the Therapeutic Angiogenesis in Erectile Conditions**

---

**Dallas, TX** - Venturis Therapeutics, Inc. ("VT" or the "Company") today announced the issuance of U.S. Patent No. 10,433,783 entitled "Therapeutic Angiogenesis for Treating in Erectile Conditions". This is Venturis' 2nd patent for Erectile Conditions and adds to Venturis' issued U.S. Patents for methods of detecting, imaging, analyzing, diagnosing and/or treating vascular disorders and related conditions of the human and mammalian body in males and/or females. This intellectual property is directed to improvements in erectile dysfunction and related conditions that can be achieved by increasing angiogenesis at the target anatomical site.

This patent allows Venturis to operate in a wider field to develop breakthrough methods and therapies to treat these oftendistressing conditions in large patient populations. We are very pleased to be granted this new utility patent in Erectile Dysfunction in the United States. As a company, we are dedicated to securing intellectual property as we expand and develop our therapeutic programs," stated Venturis' Chairman, President, and CEO, Calvin Wallen III.

### **ABOUT VENTURIS THERAPEUTICS**

Venturis Therapeutics, Inc. is a biopharmaceutical company developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease, peripheral artery disease, erectile dysfunction, stroke, and spinal disk disease. The active pharmaceutical ingredient ("API") in our drug candidates is FGF-1, a human protein that stimulates the growth of new blood vessels, thereby increasing the blood supply to ischemic organs and tissues.

### **FORWARD LOOKING STATEMENTS**

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of VT drug candidates, market acceptance of VT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage, and financial performance. Additionally, until VT is cash flow positive from operations, the Company is dependent upon raising capital to fund its operations and meet its obligations as they come due. There can be no assurance that VT will be able to raise the necessary capital when needed.

SOURCE: Venturis Therapeutics, Inc.

---